Table 1.
Baseline demographic characteristics, health care utilization, and IBD-related medication use in the 12 months before the initiation of index biologic, in obese vs nonobese patients with IBD
| Variable | Obese (n = 524) | Nonobese (n = 5,463) |
| Demographic variables | ||
| Mean age ± SD, yr | 47 ± 14 | 41 ± 15 |
| Sex (% males) | 39.5 | 51.5 |
| Race/ethnicity (%) White African American Others |
69.9 14.7 15.4 |
72.5 11.9 15.6 |
| IBD phenotype Crohn's disease (%) Ulcerative colitis (%) |
55.3 44.7 |
58.3 41.7 |
| Mean (±SD) follow-up after starting biologic (in mo) | 13.6 ± 11.5 | 14.6 ± 13.5 |
| Health care utilization and comorbidities (baseline 12 mo before biologic initiation) | ||
| Emergency department visits (% of pts with ≥1) | 59.7 | 46.7 |
| Hospitalization (% of pts with ≥1) | 38.8 | 28.0 |
| Abdominal imaging (% of pts with ≥1) | 60.3 | 54.0 |
| Endoscopic procedures (% of pts with ≥1) | 79.4 | 73.8 |
| Abdominal surgery (% of pts with ≥1) | 12.9 | 11.4 |
| Mean (±SD) Elixhauser score Elixhauser score 2–3 Elixhauser score 4 or more |
3.8 ± 2.5 40.6 44.1 |
1.6 ± 1.8 28.7 13.4 |
| Major comorbidities Chronic obstructive lung disease Diabetes with or without complication Hypertension with or without complication Anemia |
20.2 33.6 54.4 27.8 |
11.9 7.7 19.8 24.5 |
| Serious infection (% of pts with ≥1) | 12.1 | 7.5 |
| IBD-related medication use | ||
| TNFα antagonists (at index date) (%) | 74.5 | 78.4 |
| Vedolizumab (at index date) (%) | 21.9 | 17.3 |
| Recent immunomodulator use (within 3 mo before biologic initiation) | 14.3 | 17.2 |
| Oral corticosteroids (in baseline 12 mo), % | 78.1 | 74.1 |
| Opiates (in baseline 12 mo), % | 53.7 | 40.9 |
IBD, inflammatory bowel disease; pts, patients; TNF, tumor necrosis factor.